Antonio Anzueto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10863790/publications.pdf

Version: 2024-02-01

235	53,261	8172	1385
papers	citations	76 h-index	222 g-index

236	236	236	35952
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 347-365.	2.5	7,792
2	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 532-555.	2.5	5,801
3	Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clinical Infectious Diseases, 2007, 44, S27-S72.	2.9	5,203
4	International Study of the Prevalence and Outcomes of Infection in Intensive Care Units. JAMA - Journal of the American Medical Association, 2009, 302, 2323.	3.8	2,682
5	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 557-582.	2.5	2,393
6	Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2010, 363, 1128-1138.	13.9	2,359
7	Guidelines for the Management of Adults with Community-acquired Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2001, 163, 1730-1754.	2.5	2,041
8	Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. American Journal of Respiratory and Critical Care Medicine, 2019, 200, e45-e67.	2.5	2,013
9	Characteristics and Outcomes in Adult Patients Receiving Mechanical Ventilation<SUBTITLE>A 28-Day International Study</SUBTITLE>. JAMA - Journal of the American Medical Association, 2002, 287, 345.	3.8	1,398
10	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. European Respiratory Journal, 2019, 53, 1900164.	3.1	1,223
11	Evolution of Mechanical Ventilation in Response to Clinical Research. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 170-177.	2.5	1,133
12	Evolution of Mortality over Time in Patients Receiving Mechanical Ventilation. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 220-230.	2.5	999
13	Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock*. Critical Care Medicine, 2004, 32, 21-30.	0.4	948
14	Risk Factors for Extubation Failure in Patients Following a Successful Spontaneous Breathing Trial. Chest, 2006, 130, 1664-1671.	0.4	885
15	Noninvasive Positive-Pressure Ventilation for Respiratory Failure after Extubation. New England Journal of Medicine, 2004, 350, 2452-2460.	13.9	794
16	How Is Mechanical Ventilation Employed in the Intensive Care Unit?. American Journal of Respiratory and Critical Care Medicine, 2000, 161, 1450-1458.	2.5	695
17	Aerosolized Surfactant in Adults with Sepsis-Induced Acute Respiratory Distress Syndrome. New England Journal of Medicine, 1996, 334, 1417-1422.	13.9	560
18	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. European Respiratory Journal, 2017, 49, 1700214.	3.1	536

#	Article	IF	Citations
19	Effect of Corticosteroids on Treatment Failure Among Hospitalized Patients With Severe Community-Acquired Pneumonia and High Inflammatory Response. JAMA - Journal of the American Medical Association, 2015, 313, 677.	3.8	428
20	Silver-Coated Endotracheal Tubes and Incidence of Ventilator-Associated Pneumonia. JAMA - Journal of the American Medical Association, 2008, 300, 805.	3.8	414
21	Ventilator settings as a risk factor for acute respiratory distress syndrome in mechanically ventilated patients. Intensive Care Medicine, 2005, 31, 922-926.	3.9	396
22	Tiotropium Respimat Inhaler and the Risk of Death in COPD. New England Journal of Medicine, 2013, 369, 1491-1501.	13.9	318
23	Informe 2017 de la Iniciativa Global para el DiagnÃ³stico, Tratamiento y PrevenciÃ³n de la Enfermedad Pulmonar Obstructiva CrÃ³nica: Resumen Ejecutivo de GOLD. Archivos De Bronconeumologia, 2017, 53, 128-149.	0.4	312
24	Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report. Respirology, 2017, 22, 575-601.	1.3	299
25	Outcome of mechanically ventilated patients who require a tracheostomy*. Critical Care Medicine, 2005, 33, 290-298.	0.4	293
26	Hospitalized Exacerbations of COPD. Chest, 2015, 147, 999-1007.	0.4	269
27	Characteristics and Outcomes of Ventilated Patients According to Time to Liberation from Mechanical Ventilation. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 430-437.	2.5	253
28	Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 324-330.	2.5	221
29	Incidence, risk factors and outcome of barotrauma in mechanically ventilated patients. Intensive Care Medicine, 2004, 30, 612-619.	3.9	219
30	Use of Sedatives and Neuromuscular Blockers in a Cohort of Patients Receiving Mechanical Ventilation. Chest, 2005, 128, 496-506.	0.4	216
31	Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respiratory Medicine,the, 2014, 2, 472-486.	5.2	214
32	Effect of fluticasone propionate/salmeterol (250/50Î¼g) or salmeterol (50Î¼g) on COPD exacerbations. Respiratory Medicine, 2008, 102, 1099-1108.	1.3	211
33	GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respiratory Medicine,the, 2013, 1, 43-50.	5.2	209
34	Antibiotics Are Associated With Lower Relapse Rates in Outpatients With Acute Exacerbations of COPD. Chest, 2000, 117, 1345-1352.	0.4	206
35	Outcome of reintubated patients after scheduled extubation. Journal of Critical Care, 2011, 26, 502-509.	1.0	203
36	Effects of prolonged controlled mechanical ventilation on diaphragmatic function in healthy adult baboons. Critical Care Medicine, 1997, 25, 1187-1190.	0.4	201

#	Article	IF	Citations
37	Cardiovascular effects of the nitric oxide synthase inhibitor NG-methyl-l-arginine hydrochloride (546C88) in patients with septic shock: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002)*. Critical Care Medicine, 2004, 32, 13-20.	0.4	188
38	The Relation of Pneumothorax and Other Air Leaks to Mortality in the Acute Respiratory Distress Syndrome. New England Journal of Medicine, 1998, 338, 341-346.	13.9	186
39	A Comparative Study of Community-Acquired Pneumonia Patients Admitted to the Ward and the ICU. Chest, 2008, 133, 610-617.	0.4	186
40	Late Admission to the ICU in Patients With Community-Acquired Pneumonia Is Associated With Higher Mortality. Chest, 2010, 137, 552-557.	0.4	179
41	Management and outcome of mechanically ventilated neurologic patients*. Critical Care Medicine, 2011, 39, 1482-1492.	0.4	176
42	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Archivos De Bronconeumologia, 2017, 53, 128-149.	0.4	173
43	Effects of guideline-concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia. American Journal of Medicine, 2004, 117, 726-731.	0.6	169
44	Severe hypercapnia and outcome of mechanically ventilated patients with moderate or severe acute respiratory distress syndrome. Intensive Care Medicine, 2017, 43, 200-208.	3.9	168
45	Airway pressures, tidal volumes, and mortality in patients with acute respiratory distress syndrome. Critical Care Medicine, 2005, 33, 21-30.	0.4	166
46	An Official American Thoracic Society/European Respiratory Society Statement: Research Questions in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 191, e4-e27.	2.5	166
47	The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respiratory Research, 2005, 6, 82.	1.4	159
48	Effect of Fluticasone Propionate/Salmeterol (250/50) on COPD Exacerbations and Impact on Patient Outcomes. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2009, 6, 320-329.	0.7	154
49	Association of Azithromycin With Mortality and Cardiovascular Events Among Older Patients Hospitalized With Pneumonia. JAMA - Journal of the American Medical Association, 2014, 311, 2199.	3.8	150
50	Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. Lancet Respiratory Medicine,the, 2016, 4, 731-741.	5.2	147
51	Increased mortality associated with meticillin-resistant Staphylococcus aureus (MRSA) infection in the Intensive Care Unit: results from the EPIC II study. International Journal of Antimicrobial Agents, 2011, 38, 331-335.	1.1	145
52	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. European Respiratory Journal, 2015, 45, 879-905.	3.1	138
53	Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2018, 141, 2037-2047.e10.	1.5	138
54	Population-Based Study of Statins, Angiotensin II Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors on Pneumonia-Related Outcomes. Clinical Infectious Diseases, 2012, 55, 1466-1473.	2.9	137

#	Article	IF	Citations
55	Efficacy of Oral Ciprofloxacin vs. Clarithromycin for Treatment of Acute Bacterial Exacerbations of Chronic Bronchitis. Clinical Infectious Diseases, 1998, 27, 730-768.	2.9	135
56	Exacerbations of Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2007, 4, 554-564.	3.5	135
57	Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. European Respiratory Journal, 2017, 50, 1602265.	3.1	131
58	Incidence, risk factors, and outcome of ventilator-associated pneumonia. Journal of Critical Care, 2006, 21, 56-65.	1.0	127
59	Airway Pressures and Early Barotrauma in Patients with Acute Lung Injury and Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 978-982.	2.5	125
60	Severe Pneumococcal Pneumonia Causes Acute Cardiac Toxicity and Subsequent Cardiac Remodeling. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 609-620.	2.5	120
61	Bronchopulmonary Segmental Lavage with Surfaxin (KL₄-Surfactant) for Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine, 1999, 160, 1188-1195.	2.5	119
62	Use of sedatives, opioids, and neuromuscular blocking agents in patients with acute lung injury and acute respiratory distress syndrome*. Critical Care Medicine, 2008, 36, 1083-1088.	0.4	117
63	COPDGeneÂ® 2019: Redefining the Diagnosis of Chronic Obstructive Pulmonary Disease. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2019, 6, 384-399.	0.5	112
64	Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting Î²₂-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE²SPOND). A Randomized Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 559-567.	2.5	109
65	LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. International Journal of COPD, 2017, Volume 12, 907-922.	0.9	109
66	Ventilator-associated pneumonia in adults in developing countries: a systematic review. International Journal of Infectious Diseases, 2008, 12, 505-512.	1.5	105
67	Treatment of Community-Acquired Pneumonia in Immunocompromised Adults. Chest, 2020, 158, 1896-1911.	0.4	105
68	Long-term prognosis in community-acquired pneumonia. Current Opinion in Infectious Diseases, 2013, 26, 151-158.	1.3	104
69	Outcome of older patients receiving mechanical ventilation. Intensive Care Medicine, 2004, 30, 639-646.	3.9	101
70	Economic Burden of Ventilator-Associated Pneumonia Based on Total Resource Utilization. Infection Control and Hospital Epidemiology, 2010, 31, 509-515.	1.0	100
71	Community-acquired pneumonia in elderly patients. Aging Health, 2009, 5, 763-774.	0.3	95
72	Incidence of Cardiovascular Events After Hospital Admission for Pneumonia. American Journal of Medicine, 2011, 124, 244-251.	0.6	91

#	Article	IF	Citations
73	A Randomized Trial Comparing the Cardiac Rhythm Safety of Moxifloxacin vs Levofloxacin in Elderly Patients Hospitalized With Community-Acquired Pneumonia. Chest, 2005, 128, 3398-3406.	0.4	89
74	Airway pressure release ventilation versus assist-control ventilation: a comparative propensity score and international cohort study. Intensive Care Medicine, 2010, 36, 817-827.	3.9	86
75	Observational Study of Inhaled Corticosteroids on Outcomes for COPD Patients with Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 312-316.	2.5	83
76	Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): Efficacy and Safety of Moxifloxacin Therapy versus That of Levofloxacin Therapy. Clinical Infectious Diseases, 2006, 42, 73-81.	2.9	81
77	Efficacy of Corticosteroid Therapy in Patients With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease Receiving Ventilatory Support. Archives of Internal Medicine, 2011, 171, 1939.	4.3	78
78	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. European Respiratory Review, 2015, 24, 159-172.	3.0	72
79	Prediction of Acute Respiratory Disease in Current and Former Smokers With and Without COPD. Chest, 2014, 146, 941-950.	0.4	71
80	Pneumonia in Patients with Chronic Obstructive Pulmonary Disease. Tuberculosis and Respiratory Diseases, 2018, 81, 187.	0.7	70
81	Antibiotics for treatment and prevention ofÂexacerbations of chronic obstructive pulmonary disease. Journal of Infection, 2013, 67, 497-515.	1.7	69
82	Moxifloxacinversusamoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. European Respiratory Journal, 2012, 40, 17-27.	3.1	68
83	Understanding the impact of chronic obstructive pulmonary disease exacerbations on patient health and quality of life. European Journal of Internal Medicine, 2020, 73, 1-6.	1.0	67
84	Severe Community-Acquired Pneumonia. Infectious Disease Clinics of North America, 2009, 23, 503-520.	1.9	65
85	Blood eosinophil count and exacerbation risk in patients with COPD. European Respiratory Journal, 2017, 50, 1700761.	3.1	64
86	Prediction of death and prolonged mechanical ventilation in acute lung injury. Critical Care, 2007, 11, R53.	2.5	63
87	The impact of empiric antimicrobial therapy with a Î²-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia. Critical Care, 2006, 10, R8.	2.5	60
88	A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. Respiratory Medicine, 2012, 106, 970-979.	1.3	60
89	Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1268-1278.	2.5	60
90	Activity of a silver-coated endotracheal tube in preclinical models of ventilator-associated pneumonia and a study after extubation*. Critical Care Medicine, 2010, 38, 1135-1140.	0.4	58

#	Article	IF	Citations
91	Factors associated with change in exacerbation frequency in COPD. Respiratory Research, 2013, 14, 79.	1.4	58
92	Hypocapnia and Hypercapnia Are Predictors for ICU Admission and Mortality in Hospitalized Patients With Community-Acquired Pneumonia. Chest, 2012, 142, 1193-1199.	0.4	56
93	Antibiotic Therapy and 48-Hour Mortality for Patients with Pneumonia. American Journal of Medicine, 2006, 119, 859-864.	0.6	55
94	Genetic Association and Risk Scores in a Chronic Obstructive Pulmonary Disease Meta-analysis of 16,707 Subjects. American Journal of Respiratory Cell and Molecular Biology, 2017, 57, 35-46.	1.4	55
95	Management and outcome of mechanically ventilated patients after cardiac arrest. Critical Care, 2015, 19, 215.	2.5	54
96	Association between ventilatory settings and development of acute respiratory distress syndrome in mechanically ventilated patients due to brain injury. Journal of Critical Care, 2017, 38, 341-345.	1.0	54
97	Clinical Epidemiology of COPD. Chest, 2019, 156, 228-238.	0.4	53
98	The impact of prior outpatient ACE inhibitor use on 30-day mortality for patients hospitalized with community-acquired pneumonia. BMC Pulmonary Medicine, 2005, 5, 12.	0.8	49
99	The Tiotropium Safety and Performance in RespimatÂ® Trial (TIOSPIRÂ®), a large scale, randomized, controlled, parallel-group trial-design and rationale. Respiratory Research, 2013, 14, 40.	1.4	48
100	<i>Pseudomonas aeruginosa</i> in Chronic Obstructive Pulmonary Disease Patients with Frequent Hospitalized Exacerbations: A Prospective Multicentre Study. Respiration, 2018, 96, 417-424.	1.2	45
101	Clinical Approach to the Therapy of Asthma-COPD Overlap. Chest, 2019, 155, 168-177.	0.4	44
102	Antibiotics for Acute and Chronic Respiratory Infection in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1052-1057.	2.5	42
103	A score to predict short-term risk of COPD exacerbations (SCOPEX). International Journal of COPD, 2015, 10, 201.	0.9	42
104	Prognosis factors and outcome of community-acquired pneumonia needing mechanical ventilation. Journal of Critical Care, 2005, 20, 230-238.	1.0	41
105	Impact of sedation and analgesia during noninvasive positive pressure ventilation on outcome: a marginal structural model causal analysis. Intensive Care Medicine, 2015, 41, 1586-1600.	3.9	41
106	Combined Forced Expiratory Volume in 1 Second and Forced Vital Capacity Bronchodilator Response, Exacerbations, and Mortality in Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 2019, 16, 826-835.	1.5	41
107	Determinants of exacerbation risk in patients with COPD in the TIOSPIR study. International Journal of COPD, 2017, Volume 12, 3391-3405.	0.9	40
108	Comorbidities of COPD Have a Major Impact on Clinical Outcomes, Particularly in African Americans. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2014, 1, 105-114.	0.5	40

#	Article	IF	Citations
109	Inter-country variability over time in the mortality of mechanically ventilated patients. Intensive Care Medicine, 2020, 46, 444-453.	3.9	39
110	Assessing Short-term Deterioration in Maintenance-naÃ¯ve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials. Advances in Therapy, 2016, 33, 2188-2199.	1.3	37
111	Chronic Respiratory Infection in Patients with Chronic Obstructive Pulmonary Disease: What Is the Role of Antibiotics?. International Journal of Molecular Sciences, 2017, 18, 1344.	1.8	36
112	Lobar Emphysema Distribution Is Associated With 5-Year Radiological Disease Progression. Chest, 2018, 153, 65-76.	0.4	36
113	Diagnosis of Pulmonary Malignancy after Hospitalization for Pneumonia. American Journal of Medicine, 2010, 123, 66-71.	0.6	35
114	A new perspective on optimal care for patients with COPD. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2011, 20, 205-209.	2.5	35
115	Acute Kidney Injury in Mechanically Ventilated Patients. Shock, 2017, 48, 411-417.	1.0	35
116	Critically Ill Elderly Adults with Infection: Analysis of the Extended Prevalence of Infection in Intensive Care Study. Journal of the American Geriatrics Society, 2013, 61, 2065-2071.	1.3	34
117	Role of infection in exacerbations of chronic obstructive pulmonary disease. Current Opinion in Pulmonary Medicine, 2015, 21, 278-283.	1.2	34
118	Risk factors and antibiotic therapy in <scp>P</scp>.â€‰aeruginosa communityâ€acquired pneumonia. Respirology, 2015, 20, 660-666.	1.3	34
119	Severe community-acquired pneumonia: current outcomes, epidemiology, etiology, and therapy. Current Opinion in Infectious Diseases, 2001, 14, 703-709.	1.3	33
120	A Non-Human Primate Model of Severe Pneumococcal Pneumonia. PLoS ONE, 2016, 11, e0166092.	1.1	33
121	EARLY AND SMALL CHANGES IN SERUM CREATININE CONCENTRATIONS ARE ASSOCIATED WITH MORTALITY IN MECHANICALLY VENTILATED PATIENTS. Shock, 2010, 34, 109-116.	1.0	32
122	An Assessment of the Acute Kidney Injury Network Creatinine-Based Criteria in Patients Submitted to Mechanical Ventilation. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1547-1555.	2.2	31
123	Comparison of two guideline-concordant antimicrobial combinations in elderly patients hospitalized with severe community-acquired pneumonia*. Critical Care Medicine, 2012, 40, 2310-2314.	0.4	31
124	Predictors of rehospitalization after admission for pneumonia in the veterans affairs healthcare system. Journal of Hospital Medicine, 2014, 9, 379-383.	0.7	29
125	Outcomes of Patients Ventilated With Synchronized Intermittent Mandatory Ventilation With Pressure Support. Chest, 2010, 137, 1265-1277.	0.4	28
126	Disparities of Care for African-Americans and Caucasians with Community-Acquired Pneumonia: A Retrospective Cohort Study. BMC Health Services Research, 2010, 10, 143.	0.9	28

#	Article	IF	Citations
127	Prior cardiovascular disease increases long-term mortality in COPD patients with pneumonia. European Respiratory Journal, 2014, 43, 36-42.	3.1	28
128	Antibiotic prophylaxis in COPD: Why, when, and for whom?. Pulmonary Pharmacology and Therapeutics, 2015, 32, 119-123.	1.1	28
129	Complication of Community-Acquired Pneumonia (Including Cardiac Complications). Seminars in Respiratory and Critical Care Medicine, 2016, 37, 897-904.	0.8	26
130	The Role of Fixed-Dose Dual Bronchodilator Therapy in Treating COPD. American Journal of Medicine, 2018, 131, 608-622.	0.6	26
131	Characterisation of exacerbations of chronic bronchitis and COPD in Europe: the GIANT study. Therapeutic Advances in Respiratory Disease, 2009, 3, 267-277.	1.0	25
132	MUSCLE DYSFUNCTION IN THE INTENSIVE CARE UNIT. Clinics in Chest Medicine, 1999, 20, 435-452.	0.8	24
133	Moxifloxacin: a respiratory fluoroquinolone. Expert Opinion on Pharmacotherapy, 2008, 9, 1755-1772.	0.9	24
134	Normativa SEPAR: neumonÃa nosocomial. Archivos De Bronconeumologia, 2011, 47, 510-520.	0.4	24
135	The Association of Cardioprotective Medications with Pneumonia-Related Outcomes. PLoS ONE, 2014, 9, e85797.	1.1	24
136	Infections and Use of Antibiotics in Patients Admitted for Severe Acute Pancreatitis: Data from the EPIC II Study. Surgical Infections, 2014, 15, 394-398.	0.7	24
137	Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia. Chest, 2021, 159, 58-72.	0.4	24
138	Clinical Course of Chronic Obstructive Pulmonary Disease: Review of Therapeutic Interventions. American Journal of Medicine, 2006, 119, 46-53.	0.6	23
139	A new two-step algorithm for the treatment of COPD. European Respiratory Journal, 2017, 49, 1602200.	3.1	23
140	Effects of hydrogen chloride on respiratory response and pulmonary function of the baboon. Journal of Toxicology and Environmental Health - Part A: Current Issues, 1988, 23, 473-493.	1.1	22
141	Effect of tiotropium on COPD exacerbations: A systematic review. Respiratory Medicine, 2016, 114, 1-8.	1.3	22
142	Susceptibility to exacerbation in COPD. Lancet Respiratory Medicine,the, 2017, 5, e29.	5.2	21
143	Chronic Obstructive Pulmonary Disease Exacerbations: A Need for Action. American Journal of Medicine, 2018, 131, 15-22.	0.6	21
144	A clinical prediction model for hospitalized COPD exacerbations based on “treatable traits” . International Journal of COPD, 2019, Volume 14, 719-728.	0.9	21

#	Article	IF	Citations
145	Clarithromycin in 2003: sustained efficacy and safety in an era of rising antibiotic resistance. International Journal of Antimicrobial Agents, 2004, 24, 1-17.	1.1	20
146	What is the Best Antimicrobial Treatment for Severe Community-Acquired Pneumonia (Including the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf North America, 2013, 27, 133-147.	1.9	20
147	Short-course fluoroquinolone therapy in exacerbations of chronic bronchitis and COPD. Respiratory Medicine, 2010, 104, 1396-1403.	1.3	19
148	Shortness of Breath with Daily Activities questionnaire: validation and responder thresholds in patients with chronic obstructive pulmonary disease. BMJ Open, 2013, 3, e003048.	0.8	19
149	The Tiotropium Safety and Performance in RespimatÂ® (TIOSPIRÂ®) Trial: Spirometry Outcomes. Respiratory Research, 2015, 16, 107.	1.4	19
150	Health careâ€“associated pneumonia in the intensive care unit: Guideline-concordant antibiotics and outcomes. Journal of Critical Care, 2016, 36, 265-271.	1.0	19
151	Airway Mucin 2 Is Decreased in Patients with Severe Chronic Obstructive Pulmonary Disease with Bacterial Colonization. Annals of the American Thoracic Society, 2016, 13, 636-642.	1.5	19
152	Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFTÂ® trial. Respiratory Research, 2018, 19, 196.	1.4	19
153	Barotrauma in mechanically ventilated patients with Coronavirus disease 2019: a survey of 38 hospitals in Lombardy, Italy. Minerva Anestesiologica, 2021, 87, 193-198.	0.6	19
154	Evaluation of withdrawal of maintenance tiotropium in COPD. Respiratory Medicine, 2009, 103, 1415-1420.	1.3	18
155	Primary Care Management of Chronic Obstructive Pulmonary Disease to Reduce Exacerbations and Their Consequences. American Journal of the Medical Sciences, 2010, 340, 309-318.	0.4	18
156	Improving the 2007 Infectious Disease Society of America/American Thoracic Society severe community-acquired pneumonia criteria to predict intensive care unit admission. Journal of Critical Care, 2013, 28, 284-290.	1.0	18
157	Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol. International Journal of COPD, 2014, 9, 813.	0.9	18
158	Optimizing bronchodilation in the prevention of COPD exacerbations. Respiratory Research, 2017, 18, 125.	1.4	18
159	Prediction and Outcome of Intensive Care Unit-Acquired Paresis. Journal of Intensive Care Medicine, 2018, 33, 16-28.	1.3	18
160	Seasonal variations in exacerbations and deaths in patients with COPD during the TIOSPIR® trial. International Journal of COPD, 2018, Volume 13, 605-616.	0.9	18
161	Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 1513-1525.	1.3	18
162	Evolution Over Time of Ventilatory Management and Outcome of Patients With Neurologic Disease*. Critical Care Medicine, 2021, 49, 1095-1106.	0.4	17

#	Article	IF	Citations
163	Association of Hypoglycemia With Mortality for Subjects Hospitalized With Pneumonia. American Journal of the Medical Sciences, 2010, 339, 239-243.	0.4	16
164	Considerations for the Correct Diagnosis of COPD and Its Management With Bronchodilators. Chest, 2018, 154, 242-248.	0.4	16
165	Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials. Respiratory Medicine, 2018, 143, 67-73.	1.3	16
166	Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study. European Respiratory Journal, 2018, 52, 1801334.	3.1	16
167	Association of Hydrophilic Versus Lipophilic Angiotensin-Converting Enzyme Inhibitor Use on Pneumonia-Related Mortality. American Journal of the Medical Sciences, 2008, 336, 462-466.	0.4	14
168	Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial. Npj Primary Care Respiratory Medicine, 2015, 25, 15067.	1.1	14
169	Association of atypical antipsychotics and mortality for patients hospitalised with pneumonia. ERJ Open Research, 2019, 5, 00223-2018.	1.1	14
170	Tiotropium in chronic obstructive pulmonary disease â€“ a review of clinical development. Respiratory Research, 2020, 21, 199.	1.4	14
171	Identifying patients at risk of late recovery (â‰¥8 days) from acute exacerbation of chronic bronchitis and COPD. Respiratory Medicine, 2012, 106, 1258-1267.	1.3	13
172	Efficacy of tiotropium in the prevention of exacerbations of COPD. Therapeutic Advances in Respiratory Disease, 2009, 3, 103-111.	1.0	12
173	TIOtropium Safety and Performance In Respimat Â® (TIOSPIR TM): Analysis of Asian cohort of COPD patients. Respirology, 2016, 21, 1397-1403.	1.3	12
174	A novel study design for antibiotic trials in acute exacerbations of COPD: MAESTRAL methodology. International Journal of COPD, 2011, 6, 373.	0.9	11
175	Effects of Inhaled Corticosteroids on Pneumonia Severity and Antimicrobial Resistance. Respiratory Care, 2013, 58, 1489-1494.	0.8	11
176	Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee. Annals of the American Thoracic Society, 2019, 16, 29-39.	1.5	11
177	Mortality in Monotherapy versus Combination Therapy in Severe Community-Acquired Pneumonia: A Systematic Revie. Chest, 2003, 124, 190S.	0.4	10
178	Antimicrobial Treatment of Community-Acquired Pneumonia. Clinics in Chest Medicine, 2005, 26, 65-73.	0.8	10
179	SEPAR Guidelines for Nosocomial Pneumonia. Archivos De Bronconeumologia, 2011, 47, 510-520.	0.4	10
180	Macrolide Antibiotics for Prevention of Chronic Obstructive Pulmonary Disease Exacerbations: Are We There Yet?. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 1-2.	2.5	10

#	Article	IF	Citations
181	Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations. International Journal of COPD, 2016, 11, 381.	0.9	10
182	The Association Between Major Depressive Disorder and Outcomes in Older Veterans Hospitalized With Pneumonia. American Journal of the Medical Sciences, 2018, 355, 21-26.	0.4	10
183	Tiotropium/Olodaterol Decreases Exacerbation Rates Compared with Tiotropium in a Range of Patients with COPD: Pooled Analysis of the TONADOÂ®/DYNAGITOÂ® Trials. Advances in Therapy, 2020, 37, 4266-4279.	1.3	10
184	Machine learning predicts mortality based on analysis of ventilation parameters of critically ill patients: multi-centre validation. BMC Medical Informatics and Decision Making, 2021, 21, 152.	1.5	10
185	Common medications that increase the risk for developing community-acquired pneumonia. Current Opinion in Infectious Diseases, 2010, 23, 145-151.	1.3	9
186	Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β₂-agonist fixed-dose combination: RE²SPOND rationale and study design. International Journal of COPD, 2016, Volume 11, 1921-1928.	0.9	9
187	Time To Revise COPD Treatment Algorithm . International Journal of COPD, 2019, Volume 14, 2229-2234.	0.9	9
188	The role of new therapies for severe community-acquired pneumonia. Current Opinion in Infectious Diseases, 2006, 19, 557-564.	1.3	8
189	Review: Novel targets in the management of pneumonia. Therapeutic Advances in Respiratory Disease, 2008, 2, 387-400.	1.0	8
190	Optimizing management of chronic obstructive pulmonary disease in the upcoming decade. International Journal of COPD, 2011, 6, 47.	0.9	8
191	The Paradoxical Effect on Pneumonia of Chronic Inhaled Corticosteroids. Clinical Pulmonary Medicine, 2013, 20, 6-10.	0.3	8
192	Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial. BMJ Open, 2015, 5, e009015.	0.8	8
193	Chromogranin A levels and mortality in patients with severe sepsis. Biomarkers, 2015, 20, 171-176.	0.9	8
194	Easy prognostic assessment of concomitant organ failure in critically ill patients undergoing mechanical ventilation. European Journal of Internal Medicine, 2019, 70, 18-23.	1.0	8
195	Effectiveness of Beta-Lactam plus Doxycycline for Patients Hospitalized with Community-Acquired Pneumonia. Clinical Infectious Diseases, 2022, 75, 118-124.	2.9	8
196	Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT studies. International Journal of COPD, 2009, 4, 185-201.	0.9	8
197	Surfactant supplementation in the lung. Respiratory Care Clinics of North America, 2002, 8, 211-236.	0.5	7
198	Adjunctive Therapy to Mechanical Ventilation: Surfactant Therapy, Liquid Ventilation, and Prone Position. Clinics in Chest Medicine, 2006, 27, 637-654.	0.8	6

#	Article	IF	Citations
199	Impact of prior outpatient antibiotic use on mortality for community acquired pneumonia: a retrospective cohort study. BMC Research Notes, 2008, 1, 120.	0.6	6
200	Evaluation of the IDSA/ATS Minor Criteria for Severe Community-Acquired Pneumonia. Hospital Practice (1995), 2012, 40, 158-164.	0.5	6
201	Prognostic factors for clinical failure of exacerbations in elderly outpatients with moderate-to-severe COPD. International Journal of COPD, 2015, 10, 985.	0.9	6
202	Impact of Cirrhosis on Pneumonia-Related Outcomes in Hospitalized Older Veterans. American Journal of the Medical Sciences, 2019, 357, 296-301.	0.4	6
203	Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD. ERJ Open Research, 2020, 6, 00187-2019.	1.1	6
204	Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD. Npj Primary Care Respiratory Medicine, 2021, 31, 29.	1.1	6
205	The Potential Role of Statins in Pneumonia. Current Respiratory Medicine Reviews, 2010, 6, 155-161.	0.1	5
206	GOLD COPD categories are not fit for purpose in primary care â€“ Authors' reply. Lancet Respiratory Medicine,the, 2013, 1, e17-e18.	5.2	5
207	Steroid Infusion for Severe Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 781-781.	2.5	4
208	Antimicrobial treatment of community-acquired pneumonia in the elderly. Aging Health, 2006, 2, 999-1011.	0.3	4
209	Reply to Bodi et al. Clinical Infectious Diseases, 2006, 42, 1345-1345.	2.9	4
210	Differences in outcomes between GOLD groups in patients with COPD in the TIOSPIR® trial. International Journal of COPD, 2016, 11, 133.	0.9	4
211	Demographic Characteristics and Clinical Outcomes in Patients from Latin America Versus the Rest of the World: A TIOSPIR Â® Post-Hoc Analysis. Archivos De Bronconeumologia, 2018, 54, 140-148.	0.4	4
212	Update in Pulmonary Disease. Annals of Internal Medicine, 2000, 133, 360.	2.0	3
213	Disease Modification in Chronic Obstructive Pulmonary Disease. Clinics in Chest Medicine, 2007, 28, 609-616.	0.8	3
214	Impact of body weight on critically ill patients: a heavy load!!. Intensive Care Medicine, 2008, 34, 1964-5.	3.9	3
215	A post hoc pooled analysis of exacerbations among US participants in randomized controlled trials of tiotropium. Respiratory Medicine, 2013, 107, 1912-1922.	1.3	3
216	Tiotropium safety in â€˜realâ€worldâ€™ populations. British Journal of Clinical Pharmacology, 2016, 82, 562-563.	1.1	3

#	Article	IF	Citations
217	Impact of prior systemic corticosteroid use in patients admitted with community-acquired pneumonia. Therapeutic Advances in Respiratory Disease, 2012, 6, 323-330.	1.0	2
218	Dual bronchodilators in chronic obstructive pulmonary disease: Evidence from randomized controlled trials and real-world studies. Respiratory Medicine: X, 2020, 2, 100016.	1.4	2
219	Pneumonia in the Elderly Hospitalized in the Department of Veteran Affairs Health Care System. Military Medicine, 2011, 176, 214-217.	0.4	2
220	Editorial. Journal of International Medical Research, 2001, 29, 49-50.	0.4	1
221	Healthcare-Associated Pneumonia: Epidemiology, Microbiology and Clinical Outcomes. , 0, , 1-10.		1
222	2473 Cardiac injury due to Streptococcus pneumoniae invasion during severe pneumococcal pneumonia in a novel nonhuman primate model. Journal of Clinical and Translational Science, 2018, 2, 6-6.	0.3	1
223	Utilization of Mechanical Ventilation for Critical Care. Lung Biology in Health and Disease, 2001, , 53-77.	0.1	1
224	Administration of Nitric Oxide Synthase Inhibitor 546C88 in Septic Shock: The authors reply. Critical Care Medicine, 2004, 32, 1625-1626.	0.4	0
225	Tidal Volume in Mechanical Ventilation: The Importance of Considering Predicted Body Weight. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 316-316.	2.5	0
226	When to Switch Therapy in Patients with Severe Community-Acquired Pneumonia. Annals of Internal Medicine, 2008, 148, 625.	2.0	0
227	A Pharmacotherapeutic Approach to Improving Health-Related Quality of Life for Patients With Chronic Obstructive Pulmonary Disease. Clinical Pulmonary Medicine, 2009, 16, 115-126.	0.3	0
228	The need to further understand who gets hospitalized for a COPD exacerbation. Multidisciplinary Respiratory Medicine, 2012, 7, 7.	0.6	0
229	Efficacy of an inhaled corticosteroid/long-acting Î²2-agonist combination in symptomatic COPD patients in GOLD groups B and D. European Respiratory Journal, 2015, 46, 255-258.	3.1	0
230	Demographic Characteristics and Clinical Outcomes in Patients from Latin America Versus the Rest of the World: A TIOSPIR Â® Post-Hoc Analysis. Archivos De Bronconeumologia, 2018, 54, 140-148.	0.4	0
231	Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD?. European Respiratory Journal, 2019, 54, 1901405.	3.1	0
232	Acute Exacerbations of Chronic Obstructive Pulmonary Disease. , 2003, , 215-254.		0
233	Emergency diagnoses and treatment of acute exacerbations of chronic obstructive pulmonary disease. , 2006, , 421-434.		0
234	Exacerbations of COPD. , 2011, , 191-209.		0

#	Article	IF	Citations
235	The Acute Effects of Azithromycin Use on Cardiovascular Mortality as Compared with <scp>Amoxicillinâ€Clavulanate</scp> in United States Veterans. Pharmacoepidemiology and Drug Safety, 2022, , .	0.9	0